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Abstract
The availability of newer, and more expensive, therapies for
patients with rheumatoid arthritis has changed treatment beyond
recognition. Disease remission is the goal for all new patients.
Studies have shown that a combination of tumour necrosis factor
(TNF)-blocking drugs and methotrexate produces superior
outcomes over monotherapy alone; however, use is limited by cost
and potential side-effects. Currently, anti-TNF therapy is normally
reserved for patients who have failed traditional disease-modifying
anti-rheumatic drugs. The question that remains is whether TNF-
blocking drugs are better used if given early; the high direct costs
are countered by both direct and indirect savings in healthcare
costs from optimal control of disease, and the benefits of early
control outweigh the increased risk of infection and malignancy.
Introduction
Rheumatoid arthritis (RA) is a progressive destructive
inflammatory disease associated with pain and disability. It
has a significant negative impact on quality of life, with job
loss and poor social functioning as well as resultant
healthcare costs to the community. Management of RA has
changed considerably within the past decade; recognition
that earlier treatment provides superior outcomes [1-5],
combined with the availability of potent biological agents, has
focused treatment aims on the induction of remission instead
of simply controlling symptoms.
Conventional therapy with disease-modifying anti-rheumatic
drugs (DMARDs) is effective in a proportion of patients;
however, the onset is slow, taking months to achieve full
effect. Also of concern is that even if good clinical response
is achieved, radiographic progression may continue [2,6-8].
Because untreated inflammation leads to damage, early
effective treatment is needed. It has been suggested that
there is a ‘therapeutic window of opportunity’ in which early
treatment may allow the modification of underlying disease
processes and the prevention of development of further
inflammation [9-11]. DMARDs are currently the first line of
therapy in early inflammatory disease; however, with the
availability of more effective (but more expensive) agents, are
we justified in now using these at the onset of disease with the
realisation that initial higher costs may lead to long-term gain?
Anti-tumour necrosis factor therapies
Tumour necrosis factor-α (TNF-α) is a potent pro-inflam-
matory cytokine that has a central role in the pathogenesis of
RA. TNF-blocking drugs were first examined in patients with
established disease [12,13]. Infliximab, a human–murine
chimaeric monoclonal antibody directed against TNF-α, was
given to patients with disease refractory to traditional
DMARD therapy and was found to suppress disease activity,
improve the quality of life and decrease the rate of
radiological progression. Control of symptoms was rapid:
more than 50% achieved a 20% reduction in the number of
tender and swollen joints within a fortnight (ACR20 response),
and 90% achieved this within 6 weeks. A combination of
infliximab and methotrexate halted joint damage in patients,
unlike methotrexate alone. This study raised the question of
whether early treatment may produce better outcomes than
the use of TNF-blocking drugs later in the disease.
Rapid clinical control
Rapid control of disease is important for management of
symptoms and maintenance of function. The ASPIRE trial
evaluated the efficacy of infliximab (3 mg/kg or 6 mg/kg) in
combination with methotrexate versus methotrexate alone in
methotrexate-naive patients with early RA [14]. Superior
clinical and functional outcomes were seen at 1 year in the
combination groups. No significant differences were observed
in clinical efficacy between the low- and high-dose infliximab
groups. More patients receiving infliximab had clinically
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meaningful improvement in health assessment questionnaire
(HAQ) scores and this was seen as early as week 2 [14,15].
Clinical remission rates at 1 year were higher in those patients
receiving infliximab compared with methotrexate alone
(disease activity score in 28 joints (DAS28) <2.6; 22.7%
versus 14.2%) [14,16]. Importantly, this study demonstrated
that the combination of methotrexate and the TNF-blocking
drug was superior to methotrexate alone in improving clinical
responses and reducing disability in early disease.
The rapid response was also seen in the ERA trial, which
compared two monotherapies; etanercept (10 mg or 25 mg
twice weekly) and methotrexate, in patients with early erosive
disease (<3 years) [17]. The primary clinical endpoint was
overall response during the first 6 months (measured by area
under the curve for ACRn). This was significantly higher in
patients receiving 25 mg of etanercept than in those
receiving methotrexate monotherapy. Although patients
receiving etanercept as monotherapy had a more rapid
clinical response, there were no differences in the
ACR20/50/70 response rates between 6 and 12 months in
the methotrexate group and in patients receiving the higher
dose of etanercept. However, the overall response (ACRn)
was better in the etanercept group than in the patients
receiving methotrexate alone.
Adalimumab, a fully humanised monoclonal antibody, was the
third TNF-blocking drug to be introduced [18]. Use in
combination with methotrexate in early disease showed rapid
disease control and better clinical outcomes than when either
was used as monotherapy. The PREMIER study [18]
included 799 patients with a disease duration of less than
3 years (mean 0.7 years). A co-primary endpoint of ACR50
response was achieved in 61% of patients undergoing
combination treatment, in comparison with 46% and 42% in
those patients receiving monotherapy with methotrexate and
adalimumab, respectively. The ACR20/50/70 responses
were significantly higher at week 2 in the combination group,
and this result was sustained over the 2-year trial period.
DAS28 remission (a score of less than 2.6) was achieved by
50% of patients in the combination group, but by only 25% in
the monotherapy groups.
The results of these studies show that TNF-blocking drugs,
used either in combination or as monotherapy, have a more
rapid clinical response than methotrexate alone in early
disease [15-18]. Although anti-TNF monotherapy resulted in
a better clinical response at 6 months than methotrexate
monotherapy, the clinical outcomes at 12 and 24 months in
those receiving a combination of TNF-blocking drugs and
methotrexate were superior to the outcomes in those
receiving either as monotherapy [14,18].
Prevention of damage
Untreated inflammation leads to damage, and it is reasonable
to predict that the earlier control achieved by TNF-blocking
drugs would give superior structural outcomes. In addition to
the superior clinical and functional outcomes, patients
receiving combination therapy in the ASPIRE trial had
superior radiological outcomes. A sub-analysis of patients
with a disease duration of less than 3 years showed that
combination therapy inhibited structural progression during
the first 2 years of therapy [14]. In this study, the radiographic
progression was defined as an increase from baseline in the
van der Heijde modification of total Sharp score that was
larger than the smallest detectable difference. No differences
were observed in radiographic changes between the
infliximab groups.
Despite the more rapid clinical improvement and better
American College of Rheumatology (ACR) response status at
6 months in early ERA patients receiving etanercept, there
was no significant difference in Sharp scores at 12 months
between the two therapies; erosions were halted in 72% of
patients receiving etanercept (25 mg) and in 60% of those
receiving methotrexate. Interestingly, an open-label extension
study showed significantly lower mean changes in Sharp
score and erosions in the group receiving etanercept (25 mg)
at 24 months in the extension study, suggesting better
efficacy of the TNF-blocking drug on long-term structural
outcome [19].
The results of the PREMIER study supported those of the
previous studies. The change in total Sharp score was
significantly lower in the combination group, indicating
significantly less radiological progression. Interestingly,
although patients receiving monotherapy had equivalent
clinical outcomes at 2 years, there was more radiographic
damage in the group receiving methotrexate [18,20]. A
similar finding was seen in the ATTRACT study (established
disease) and ASPIRE trial, with more radiographic
progression in patients receiving methotrexate monotherapy
than in the combination group, irrespective of DAS28 [21] or
ACR response status [22].
The findings in the PREMIER, ASPIRE and ERA studies
support early aggressive intervention in RA. Importantly, the
results demonstrated that a combination of methotrexate and
anti-TNF is superior to methotrexate alone in preventing
progressive joint destruction, improving clinical responses
and reducing disability in early disease. The additional
benefit of biological therapy in retarding radiographic
progression may be explained by a direct effect of the anti-
TNF agents on osteoclasts [23-25]. In contrast, patients
treated with conventional DMARDs experience structural
deterioration despite clinical remission. Unpublished results
(Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K,
Peterfy CG, Hensor E, Wakefield RJ, O’Connor PJ and
Emery P) suggest that subclinical inflammation detected by
imaging accounts for this progression and may provide a
rationale for treating these patients in apparent remission
with an anti-TNF agent.Page 3 of 7
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There is no evidence that any one TNF-blocking drug has
superior efficacy to the others. No comparative trials have
been conducted. Practical issues, such as route of adminis-
tration and patient preference, have a role in the choice of
anti-TNF agent. Concurrent administration of methotrexate is
required for infliximab and is advised for use with the other
two agents to provide the best outcomes. Studies have
suggested that patients may respond to a different anti-TNF
agent if there is an inadequate response to the first [26-29].
In one study of 24 patients switched from infliximab to
etanercept because of lack of efficacy, 80% achieved either a
‘moderate’ or ‘good’ European League Against Rheumatism
(EULAR) response [26].
Disadvantages of anti-tumour necrosis factor
therapy
Although TNF-blocking drugs have been extremely effective in
improving clinical outcomes and reducing structural damage,
there is the concern of the increased risk of serious infections
and malignancies. TNF-α, although an important pro-
inflammatory cytokine, also has a role in fighting infection and in
the regulation of tumour cells. With blockade of TNF-α comes
the concern of increased susceptibility to these problems.
The results on the increased risk of serious infection during
randomised trials in patients with RA have been inconsistent:
some trials have shown significant association [14,30] and
others no significant association [31-34]. A post-marketing
surveillance and observational studies have suggested an
increased risk of serious infections with anti-TNF therapies
[35-37]. In a recent meta-analysis of TNF-blocking drugs
(infliximab or adalimumab) in patients with RA, the threat of
serious infection was 3.6%, in contrast with 1.6% in controls
(risk ratio of 2.01) [38]. Although the population was
heterogeneous and the analysis did not control for duration of
exposure in this study, it does provide a general idea of
potential risk. Patients with RA, particularly those with severe
disease, are at increased risk of both malignancy and
infection, regardless of therapy [39-41]. In addition, patients
with severe disease are also more likely to be given TNF-
blocking drugs, and it is therefore difficult to determine with
absolute certainty the actual risk of the drug independently
from the presence of disease. Rates of opportunistic
infections such as tuberculosis are higher, and patients need
to be screened for previous exposure before the use of TNF-
blocking drugs is considered. There is also concern about
increased rates of malignancy, although results have been
conflicting. Bongantz’s meta-analysis showed that although
there was an increase in skin cancers, the rate of occurrence
of solid tumours was not increased compared with the
general population [38]. This was in contrast with a Swedish
study that did show rates of solid tumours and lymphomas to
be increased in patients with RA; however, this result was
independent of TNF-blocking drugs [42,43]. The patient
population studied may be relevant to these different results.
Serious infections and malignancies are rare occurrences,
and rates are thought to be increased by both TNF but also
by severe RA. The benefit of early control of RA may
outweigh potential risks; however, the absolute risk:benefit
ratio is unknown and needs to be studied further.
Development of antibodies against the drug – human anti-
chimaeric antibodies (HACA; infliximab) or human anti-human
antibodies (HAHA; etanercept/adalimumab) – is another
possible problem in TNF blockade therapies. Anti-infliximab
antibodies were detected in 53%, 21% and 7% of patients
treated with infliximab as monotherapy at 1, 3 and 10 mg/kg,
respectively [12]. Concomitant therapy with low-dose metho-
trexate greatly diminished the appearance of this antibody,
with incidence rates of 15%, 7%, and 0% at the three dosage
levels of infliximab, which might explain the mechanism of the
synergetic effect of methotrexate and infliximab shown in this
study [12]. In a small study, anti-infliximab antibody developed
more commonly in non-responders and in patients who had
infusion reactions [44]. In a recent study with adalimumab,
17% of patients with RA developed HAHA during 28 weeks
of treatment. The proportion was significantly higher in EULAR
non-responders than in good responders (34% versus 5%)
[45]. No such correlation was found for etanercept, although
5% of patients developed HACA [46].
The cost of the TNF-blocking drugs is probably the main
limiting factor: they are substantially more expensive than
traditional DMARDs. This direct cost of treatment needs to
be balanced with the benefits of a potentially more effective
treatment, preventing early job loss and yielding substantial
indirect cost savings. A recent review has estimated direct
costs of RA as being between 1,812 and 11,792 euros
annually per patient, with indirect costs up to 3.5-fold that
amount [47]. There are several arguments about cost
effectiveness. In a sub-analysis of the BeSt study, depending
on the way in which productivity is valued, the costs of
infliximab could be compensated for by savings in
productivity [48]. Another study reviewing costs in early
inflammatory disease found that a substantial proportion of
the costs resulted from non-health-services costs such as
travel, unpaid help from family, and work losses [49]. A recent
study has shown that the combination of adalimumab and
methotrexate has the ability to reduce RA-related job loss and
loss of work time in patients with early RA in comparison with
the use of methotrexate alone [50]. Decisions about the use
of the newer biological agents must take into account both
the costs of the medication and healthcare resources and
also the costs to society, ranging from healthcare provision
by family members to job losses.
Induction of remission with anti-TNF therapy
There has been a shift in management aims of treating
rheumatoid arthritis in that we are now aiming for disease
remission. If treatment-free remission were achievable by
early intervention with anti-TNF therapy, it would be highly
cost-effective. Preventing the development of RA before
Available online http://arthritis-research.com/content/9/3/211diagnosis would result in even more significant direct and
indirect cost savings.
Quinn and colleagues conducted a double-blind randomised
placebo-controlled trial of infliximab in addition to metho-
trexate with the aim of inducing remission in patients with RA
exhibiting magnetic resonance imaging (MRI)-proven
synovitis but little damage [51]. Patients with a disease
duration of less than 6 months received infliximab/placebo
and methotrexate every 8 weeks through to 46 weeks. The
primary endpoint was synovitis as measured by MRI. At
1 year, all MRI scores were significantly better in the infliximab
group, with no new erosions. In addition, a greater percen-
tage of patients of patients in the active group achieved
ACR50 and ACR70 improvement criteria seen from as early
as week 14, through to week 54. Response was sustained in
70% of patients in the infliximab plus methotrexate group,
with a median DAS28 of 2.05 (remission range) 1 year after
the cessation of infliximab treatment. This was the first study
to demonstrate sustained remission after a course of
induction with TNF-blocking drugs. The findings were
confirmed in a much larger study, BeSt [52].
The BeSt trial was a multi-centre, single-blind study in which
508 patients with less than 2 years of symptoms were
randomised to one of four treatment arms: sequential
monotherapy starting with methotrexate, step-up therapy from
methotrexate, step-down therapy (including initial high-dose
oral prednisolone) or combination methotrexate plus inflixi-
mab. Adjustments in doses were made at 3-monthly intervals
with the goal of achieving a DAS44 of 2.4 or less. Endpoints
were functional ability and radiographically determined
damage (measured by modified Sharp/Van der Heijde score).
A significantly greater and more rapid improvement in
function (as measured by HAQ) was seen with the initial
combination treatment and initial treatment with infliximab and
methotrexate. Mean HAQ scores at 3 months were 0.6 in
groups 3 and 4, compared with 1.0 in groups 1 and 2. At
12 months there was still a clinically detectable difference
between the groups (0.5 (groups 3 and 4) versus 0.7 (groups
1 and 2)). There was also significantly less radiographically
determined damage than with sequential monotherapy or
step-up therapy. In the group receiving infliximab, 93% did
not show radiological progression greater than the smallest
detectable difference at 1 year (versus 67% and 73% in the
monotherapy and step-up patients, respectively). Of patients
in groups 1 to 4, respectively 53%, 64%, 71% and 74%
achieved a DAS44 of 2.4 or less at 12 months. Only the
differences between group 1 and groups 3 and 4 were
significant. After good control of the disease (DAS44 ≤ 2.4)
for at least 6 months, four patients stopped infliximab
treatment; in the second year, about 50% of patients were
able to stop their infliximab treatment yet remain in remission.
This provided further support for the notion that the
combination of a TNF-blocking drug and methotrexate was
optimal in the treatment of early RA.
There are accumulating data to suggest that treating
undifferentiated arithritis with corticosteroid or methotrexate
could delay or prevent the development of full-blown RA.
Green and colleagues demonstrated the possible reversibility
of early arthritis by treatment with corticosteroid injections
before diagnosis of RA [53]. The most recent study showed
that patients with probable RA benefit from a 1-year course of
methotrexate [54]. One could speculate that blocking TNF-α,
which is a crucial factor in the pathogenesis of RA, might be
more effective in preventing disease development at a very
early stage.
Selecting candidates for TNF blockade
therapy
Identifying patients who benefit the most from TNF-blocking
therapy is a reasonable strategy for optimising the use of
these drugs. This includes determining factors for poor
prognosis in patients with early RA, identifying early arthritis
patients who are likely to have persistent disease and
predicting responses to anti-TNF agents.
Many prognostic factors have been described for RA in
several studies with radiographically determined damage or
functional disability as an outcome measure. These include
demographic (sex), environmental (smoking), clinical (joint
count), functional (HAQ), laboratory (inflammatory markers,
rheumatoid factor, anti-cyclic citrullinated peptide (anti-
CCP) antibody), radiographic (erosive joint damage) and
genetic (shared epitope) factors; however, they vary
between reports depending on the study population and the
study design. Although several predicting models have
been suggested with these variables, they have not been
validated in different cohorts, and consensus for practical
use is yet to be achieved.
Several factors have been shown to predict persistent
disease and structural damage in early arthritis; these include
disease duration, disease-specific autoantibodies (rheumatoid
factor and anti-CCP antibody) and erosions on radiograph
[55]. New imaging technology such as MRI and ultrasound
have been shown to be more sensitive than physical
examination for detecting synovial inflammation and more
precise than conventional radiography in demonstrating bone
damage, both of which may further increase the accuracy of
predicting poor outcome [56,57]. Genetic markers may also
be useful in predicting disease development and outcome.
The link between HLA-DRB1 genotype (shared epitope) and
RA has been validated for more than 30 years, although
shared epitope is strongly associated with anti-CCP antibody
and may not be an independent predictor [58]. Recently, the
association in many different populations between
polymorphism in PTPN22, a negative regulator of T-cell
activation, and RA was reported [59]. Once an accurate
prediction model is established and validated, anti-TNF
therapy for ‘high-risk’ patients with early arthritis during a
‘window of opportunity’ could be justified.
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approximately one-quarter to one-third of patients with RA
have only minor, transient clinical improvement or have no
benefit from TNF-blocking therapy [13,17]. Considering the
cost and the possible adverse event, patients who are not
likely to respond should be excluded from the indication of
anti-TNF therapy. So far, evidence from large cohorts is
limited, and no patient/disease characteristics, genetic
associations or other factors have been identified that
correlate reliably with treatment outcome. Comprehensive
investigations with enough power to provide reliable data are
warranted.
Conclusion
The ultimate goal of treatment is to induce remission such
that patients have no evidence of inflammatory disease and
should ideally be in long-term drug-free remission. Although a
proportion of early patients will have good responses to
traditional DMARDs, TNF-blocking drugs provide more rapid
control of inflammation and better long-term outcomes (in
combination with methotrexate), both clinically and in terms of
structural damage. Although there is as yet no clear evidence
that the benefit from these new drugs outweighs the high
cost and potential risks in patients with early RA, optimal use
of anti-TNF therapy exclusively for high-risk patients who are
likely to respond to treatment would change the cost–benefit
balance substantially. Furthermore, predicting poor prognosis
even before the diagnosis of RA would allow very early
intervention with TNF blockades, which may enable
‘prevention’ in the management of RA.
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